A review of interleukin-2 receptor antagonists in solid organ transplantation

Pharmacotherapy

Volumn 19, Issue 10, 1999, Pages 1127-1137

  Berard, Jennifer L ^a   Velez, Rebecca L ^a   Freeman, Richard B ^b   Tsunoda, Shirley M ^a,b  

^a NORTHEASTERN UNIVERSITY   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN; CYCLOSPORIN; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2 RECEPTOR ANTIBODY; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; TACROLIMUS;

ADULT; CADAVER; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DOSE RESPONSE; DRUG BINDING; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; FEVER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY ALLOGRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; PNEUMONIA; REVIEW; SEPSIS; THROMBOSIS;

ADULT; ANTIBODIES, MONOCLONAL; CHILD, PRESCHOOL; CLINICAL TRIALS; GRAFT REJECTION; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; ORGAN TRANSPLANTATION; RECEPTORS, INTERLEUKIN-2; RECOMBINANT FUSION PROTEINS;

EID: 0032878696     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.19.15.1127.30582     Document Type: Review

References (24)

1. Tsunoda SM, Aweeka FT. Solid organ transplantation. In: Herfindal ET, Gourley D, eds. Textbook of therapeutics. Drug and disease management, 6th ed. Baltimore: Williams & Wilkins, 1996:1841-70.
2. Feldmann F. Cell cooperation in the antibody response. In: Roitt I, Bronstoff J, Male D, eds. Immunology, 4th ed. London: Times Mirror International Publishers, 1996:8.1-8.16.
3. Nashan B, Light S, Hardie IR, Lin A, Johnson JR. Reduction of acute renal allograft rejection by daclizumab. Transplantation 1999;67(1):110-15.
4. van Gelder T, Zietse R, Mulder AH, et al. A double-blind, placebo-controlled study of monoclonal anti-interleukin-2 receptor antibody (BT563) administration to prevent acute rejection after kidney transplantation. Transplantation 1995;60(3):248-52.
5. Kirkman RL, Shapiro ME, Carpenter CB, et al. A randomized prospective trial of anti-TAC monoclonal antibody in human renal transplantation. Transplantation 1991;51(1):107-13.
6. Vincenti F, Lantz M, Birnbaum J, et al. A phase I trial of humanized anti-interleukin 2 receptor antibody in renal transplantation. Transplantation 1997;63(1):33-8.
7. Amlot PL, Rawlings E, Fernando ON, et al. Prolonged action of a chimeric interleukin-2 receptor (CD25) monoclonal antibody used in cadaveric renal transplantation. Transplantation 1995:60(7):748-56.
8. Vincenti F, Kirkman R, Light S, et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N Engl J Med 1998;338:161-5.
9. Hoffmann-La Roche Inc. Zenapax (daclizumab) package insert. Nutley, NJ;1997.
10. Vincenti F, Nashan B, Light S. Daclizumab: outcome of phase III trials and mechanism of action. Transplant Proc 1998;30:2155-8.
11. Ettenger R, Potter D, Pescovitz M, et al. Humanized monoclonal anti-interleukin-2 receptor (IL-2R) antibody daclizumab (Zenapax) in pediatric renal transplantation [abstr]. Presented at the annual meeting of the American Society of Transplant Physicians, Chicago, May 9-13, 1998.
12. Vincenti F, Ramos E, Nashan B, et al. Preliminary results of the combined use of a humanized anti-IL-2R monoclonal antibody, daclizumab, and mycophenolate mofetil without calcineurin inhibitors in renal transplantation. Presented at the annual meeting of the American Society of Transplant Physicians, Chicago, May 9-13, 1998.
13. Nashan B, Niemeyer G, Koch M, Breidenbach TH, Schlitt HJ, Raab R. Phase II clinical trial with daclizumab (Zenapax) for prevention of acute rejection in liver transplanted patients. Presented at the annual meeting of the American Society of Transplant Physicians, Chicago, May 9-13, 1998.
14. Kovarik J, Wolf P, Cisterne JM, et al. Disposition of basiliximab, an interleukin-2 receptor monoclonal antibody, in recipients of mismatched cadaver renal allografts. Transplantation 1997;64( 12): 1701-5.
15. Kovarik J, Breidenbach T, Gerbeau C, Korn A, Schmidt A, Nashan B. Disposition and immunodynamics of basiliximab in liver allograft recipients. Clin Pharmacol Ther 1998;64: 66-72.
16. Nashan B, Moore R, Amlot P, Schmidt A, Abeywickrama K, Soulillou J. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet 1997;350:1193-8.
17. Kahan BD, Rajagopalan PR, Hall ML. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonar antibody. Transplantation 1999;67(2):276-84.
18. Nashan B, Thistlewaite R, Schmidt AG, Hall M, Chodoff L. Reduced acute rejection and superior one-year renal allograft survival with basiliximab (Simulect) in patients with diabetes mellitus. Presented at the annual meeting of the American Society of Transplant Physicians, Chicago, May 9-13, 1998.
19. Breidenbach TH, Korn A, Maibucher A, et al. Basiliximab (Simulect) reduces acute rejections, CMV infections and duration of hospital stay in renal allograft patients. Presented at the annual meeting of the American Society of Transplant Physicians, Chicago, May 9-13, 1998.
20. Kovarik JM, Gerbeau C, Hall M, Schmidt AG. Influence of the duration of IL-2 receptor (IL-2) blockade on the frequency of acute rejection episodes in renal transplantation. Presented at the annual meeting of the American Society of Transplant Physicians, Chicago, May 9-13, 1998.
21. Flechner SM, Modlin CS, Serrano DP, et al. Determinants of chronic renal allograft rejection in cyclosporine-treated recipients. Transplantation 1996;62:1235-41.
22. Cardinale V, ed. Daclizumab. Drug topics redbook. Montvale, NJ: Medical Economics Co., 1999:605.
23. Cardinale V, ed. Basiliximab. Drug topics redbook. Montvale, NJ: Medical Economics Co., 1999:535.
24. Lorber M, Evans C, Fastenau J, DiCesare J, Hall M. An economic evaluation of basiliximab (Simulect) for the prevention of acute rejection in renal allograft recipients. Presented at the annual meeting of the American Society of Transplant Physicians, Chicago, May 9-13, 1998.